MDAS Related Analyst Ratings
-
UBS Maintains a 'Buy' on MedAssets (MDAS); Meeting Olympic Standards
-
Raymond James Upgrades MedAssets (MDAS) to Strong Buy
-
ISI Group Starts MedAssets (MDAS) at Overweight
-
Cowen Upgrades MedAssets (MDAS) to Outperform
-
UPDATE: UBS Upgrades MedAssets (MDAS) to Buy; RCM Growth To Accelerate
-
Lazard Starts ATHN, CERN, QSII, MDAS at Buy, MDRX, OMCL, CPSI, EHTH at Neutral, EPOC at Sell
-
Auriga Reiterates a 'Buy' on MedAssets (MDAS); See 30% Upside in Next 12-Months
-
Auriga Reiterates a 'Buy' on MedAssets (MDAS); Positive Events Continue to Confirm Thesis
-
Caris & Co. Downgrades MedAssets (MDAS) to Average
-
UBS Maintains a 'Neutral' on MedAssets (MDAS); Another Step in the Right Direction
-
Piper Jaffray Warns on Recent Contract Action for MedAssets (MDAS); Shares Moving Lower
-
Sterne Agee Starts MedAssets (MDAS) at Buy
-
Caris & Co. Upgrades MedAssets (MDAS) to Above Average
-
Barclays Maintains an 'Overweight' on MedAssets (MDAS); Hunn Departure another Challenging Update: EPS & PT Lowered
-
Auriga Maintains a 'Buy' on MedAssets (MDAS); Lowering Estimates and Price Target
-
Raymond James Upgrades MedAssets (MDAS) to Strong Buy
-
Cowen Starts MedAssets (MDAS) at Neutral, Shares Down 2.82% Today
-
Auriga Reiterates a 'Buy' on MedAssets (MDAS); A Beat and Decent Guide Should Offset Negative Sentiment
-
Goldman Sachs Starts MedAssets (MDAS) at Neutral
-
Baird Upgrades MedAssets (MDAS) to Outperform
-
Caris & Co. Starts MedAssets (MDAS) at Average
-
Leerink Swann Downgrades MedAssets (MDAS) to Market Perform; Near-Term Conviction Low
-
Oppenheimer Starts MDRX, MDAS, CPSI at Outperform, QSII, AH, EM at Perform, ATHN, CERN at Underperform
-
Auriga Reiterates a 'Buy' on MedAssets (MDAS); Tweaking Model While We Find Current Price Compelling
-
Madison Williams Upgrades MedAssets (MDAS) to Buy
-
Ticonderoga on Brokers & Asset Managers: Retail Outlook Getting Cloudier - SF, SCHW & RJF
-
Barclays Maintains an 'Overweight' on MedAssets (MDAS); Where from Here? First Take and Additional Details after Q4
-
MedAssets (MDAS) Board Should Consider Taking Co. Private -Morgan Keegan
-
Brean Murray Carret & Co. Cuts Estimates & Price Target on MedAssets (MDAS)
-
Avondale Cuts MedAssets (MDAS) to Market Perform
-
MedAssets (MDAS) Shares Plummet as Wave of Analyst Downgrades Hit Following Q4 Miss
-
Auriga Cuts Price Target on MedAssets (MDAS), Maintains Buy Rating On After Hours Quote
-
Deutsche Bank Downgrades MedAssets (MDAS) to Hold; Stepping to the Sidelines Following 4Q Miss and Reduced Guidance
-
Baird Downgrades MedAssets (MDAS) to Neutral
-
Morgan Stanley Starts Cerner (CERN), Quality Systems (QSII) at Overweight, Allscripts (MDRX), MedAssets (MDAS) at Equalweight
-
Wells Fargo Downgrades MedAssets (MDAS) to Market Perform; Forward Earnings Risk May Be Growing
-
JPMorgan Resumes Coverage on MedAssets (MDAS) at Neutral
-
UBS Reiterates a 'Neutral' on MedAssets (MDAS); Pulling Back the Curtain on Broadlane
-
Jefferies Changes Estimates and Price Target on MedAssets (MDAS) , Maintains Hold Rating
-
Deutsche Bank Reinstates MedAssets (MDAS) at Buy; Growth Story Remains Attractive Despite More Conservative Outlook
-
Baird Upgrades MedAssets (MDAS) to Outperform, Price Target $25
-
Madison Williams Upgrades MedAssets (MDAS) to Buy
-
Morgan Keegan Upgrades MedAssets (MDAS) to Outperform
-
Health Care Distribution & Technology: Barclays Capital Weekly Perspectives
-
UPDATE - UBS Initiates Coverage on MedAssets (MDAS) with a Neutral; Broadlane is a Game Changer
-
UBS Initiates Coverage on Healthcare Information Services Stocks (CERN, MDAS & QSII)
-
Brean Murray Initiates Coverage on MedAssets (MDAS) with a Buy; Point or Transform: Something for Everyone
-
Madison Williams Downgrades MedAssets, Inc. (MDAS) to Neutral
-
Madison Williams Upgrades MedAssets (MDAS) to Buy
-
Raymond James Upgrades MedAssets (MDAS) to Outperform
Back to MDAS Stock Lookup
